Navigation Links
Vermillion Reports Results for the Second Quarter 2011
Date:8/4/2011

AUSTIN, Texas, Aug. 4, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company, today reported financial results for the second quarter ended June 30, 2011. Key milestones we have achieved since the last quarterly conference call include:

  • Performance of an estimated 3,920 OVA1® tests during the second quarter of 2011, exceeding the guidance range of 3,200-3,500 tests and representing volume growth of 27% over the first quarter of 2011.
  • Publication of two articles in the June issue of Obstetrics & Gynecology, which is the official publication of the American College of Obstetricians and Gynecologists (ACOG), showing OVA1's value in evaluating women with an adnexal mass for the likelihood of ovarian cancer prior to surgery.
  • Expanded payer coverage for OVA1 with additional independent Blue Cross Blue Shield plans issuing positive coverage policies. In all, 22 independent Blue Cross Blue Shield plans, representing approximately 36 million lives, are covering OVA1. Including Medicare and other regional plans, total coverage for OVA1 is estimated to be roughly 82.5 million lives.
  • Signed an exclusive distribution agreement with Pronto Diagnostics Ltd. to make OVA1 available in Israel and related territories as we continue to expand OVA1 into international markets.  
  • Progressed our peripheral arterial disease (PAD) intended use study being performed in collaboration with the Colorado Prevention Center. The study remains on track to yield top-line data during the third quarter of 2011.
  • Enhanced our patent portfolio by announcing receipt of a notice of allowance for four patents: three for PAD and one for Alzheimer's disease.
  • Appointed Bruce Huebner, an industry veteran with 35 years of senior management experience in the diagnostic industry, to our Board of Directors.

  • '/>"/>
    SOURCE Vermillion, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
    2. Vermillion Announces Receipt of NASDAQ Panel Decision
    3. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
    4. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
    5. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
    6. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
    7. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
    8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
    9. Vermillion Announces Issuance of European Patent
    10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
    11. Stephens Initiates Coverage on Vermillion
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... , Aug. 1, 2014 AACC, a ... health through laboratory medicine, unveiled an updated brand identity ... professionals adapt to the changing healthcare environment and continue ... to physicians, so patients get the care they need. ... up AACC,s membership play an essential role in saving ...
    (Date:8/1/2014)... , Aug. 1, 2014 Research and ... "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism ... variations of SNPs in the genome of various species. ... SNP genotyping and analysis technology can analyze thousands of ...
    (Date:8/1/2014)... SEATTLE , Aug. 1, 2014 /PRNewswire/ ... announce the launch of "Data InPress" ( ... tools for integrating multidimensional image data into ... DataViewer application and Video Injection Service. ... Photo - http://photos.prnewswire.com/prnh/20140731/132409 ...
    (Date:7/31/2014)... Today BioSpace , the leading life sciences employment and ... the life sciences community in Illinois , ... , Michigan , Minnesota , ... and Wisconsin . BioMidwest is ... job postings on BioSpace originating in this region in 2013. The life ...
    Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Midwest Biotech Leaders Featured On BioSpace Map 2
    ... China, July 7 /PRNewswire-Asia-FirstCall/ -- China Clean,Energy Inc. ... "Company"),a producer of biodiesel fuel and environmentally-friendly specialty ... Republic of China,("PRC"), today announced that business conditions ... the first quarter, driven by improved demand and,higher ...
    ... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... developing breakthrough treatments for human disease, announced today that it ... LX1032 , the company,s oral drug candidate for managing ... LX1032 is designed to reduce serotonin production in patients ...
    ... The Leukemia & Lymphoma Society (LLS) and The ... initiative to develop stable and immortalized Waldenstrom,s macroglobulinemia (WM) ... researchers to test potential new treatments for the disease. ... lymphoma, characterized by B-lymphocytes in the bone marrow, and ...
    Cached Biology Technology:China Clean Energy Provides Business Update 2China Clean Energy Provides Business Update 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 2The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 3
    (Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
    (Date:7/31/2014)... how the brain processes speech, potentially increasing the ... at The University of Texas at Dallas. , ... Ear and Hearing , researchers demonstrated for the ... brain,s recognition of speech sounds. , Noise-induced hearing ... affecting an estimated 15 percent of Americans between ...
    (Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
    Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
    ... farming and relieve the pressure on overexploited fish stocks. ... fish escape? Researchers at the University of Gothenburg have ... are urging caution:,-Until further notice transgenic fish should be ... at the Department of Zoology, University of Gothenburg. ...
    ... A research report featured on the cover of the September ... http://www.fasebj.org ) describes how Australian scientists developed a new gene ... to transport their cargo into our cells. As a result ... cell,s nucleus far more efficiently than in the past, raising ...
    ... from natural coal deposits in the Gulf of Alaska ... the Exxon Valdez tanker catastrophe. This clearly disproves the ... observed environmental damage. PAH pollutants were blamed for the ... Alaska. Then a dispute erupted over the origins of ...
    Cached Biology News:Risks involved with transgenic fish 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2Bioavailable contaminants come from the Exxon Valdez oil catastrophe 2
    Interact with both DNA and RNA; fluorescence green (Em=525 nm) bound to DNA; and fluorescence red (Em=~650 nm) bound to RNA....
    One bottle containing 30 ml of protein solution and 0.1% sodium azide....
    ...
    Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
    Biology Products: